Guidelines for Implementing Medications for Opioid Use Disorder Treatment in State Prisons

People involved in the criminal justice system experience opioid use disorder (OUD) at significantly higher rates than the general population, yet access to effective treatment remains limited. Medications for Opioid Use Disorder (MOUD)—methadone, buprenorphine, and naltrexone—are proven to reduce cravings, withdrawal symptoms, overdose risk, and mortality, but are not widely available in correctional settings. Lack of MOUD during incarceration and upon release greatly increases the risk of fatal overdose and reincarceration. Expanding MOUD access supports safer facilities, improves reentry outcomes, and reduces overdose deaths, a priority shared by DOJ, HHS, SAMHSA, and partner agencies.

Completion of this self-study course provides 1 CEU hour.